…sanofi is sending all the signals that it is not looking to launch a AG, so long as there are only two competing products.
The evidence is now stronger than a mere signal. On SNY’s 3Q10 CC last week, COO Hanspeter Spek flat-out asserted that there will be no authorized generic as long as NVS/MNTA have the sole approved generic.
Thus, the implicit evidence from #msg-53738652 is now explicit.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”